Haisco(SZ:002653) Shang Hai Zheng Quan Bao·2025-06-02 20:35Group 1 - The company held its 28th meeting of the fifth board of directors on May 30, 2025, via communication voting, with all five directors participating [1][2] - The board approved the appointment of Mr. Yan Pangkai as the general manager, effective from the date of the board's approval [2][47] - The board also approved the change of the legal representative to Mr. Yan Pangkai due to business development needs [4][5] Group 2 - The board approved the appointment of Mr. Wang Ruibin as the deputy general manager, effective from the date of the board's approval [6][7] - The board approved the supplementary election of Mr. Yan Pangkai as a non-independent director candidate, pending approval from the shareholders' meeting [9][11] - The board approved the revision of the company's articles of association, which requires special resolution approval from the shareholders' meeting [11][55] Group 3 - The company received a notice of acceptance for the IND application of the innovative drug HSK47388, which is intended for the treatment of autoimmune diseases [51][52] - HSK47388 is a self-developed oral drug that has shown potential in preclinical studies for its ability to inhibit inflammation and good tolerability [52]